Cyclerion Therapeutics Inc./$CYCN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
Ticker
$CYCN
Sector
Primary listing
Employees
1
Headquarters
Website
CYCN Metrics
BasicAdvanced
$13m
-
-$1.47
1.81
-
Price and volume
Market cap
$13m
Beta
1.81
52-week high
$8.48
52-week low
$1.03
Average daily volume
45k
Financial strength
Current ratio
1.802
Quick ratio
1.647
Profitability
Gross margin (TTM)
17.06%
Net profit margin (TTM)
-264.73%
Operating margin (TTM)
-337.43%
Revenue per employee (TTM)
$1,990,000
Management effectiveness
Return on assets (TTM)
-45.81%
Return on equity (TTM)
-67.77%
Valuation
Price to revenue (TTM)
5.733
Price to book
1.99
Price to tangible book (TTM)
1.99
Price to free cash flow (TTM)
-3.185
Free cash flow yield (TTM)
-31.40%
Free cash flow per share (TTM)
-0.999
Growth
Revenue change (TTM)
-4.23%
Earnings per share change (TTM)
26.36%
3-year revenue growth (CAGR)
68.85%
3-year earnings per share growth (CAGR)
-56.22%
CYCN News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs